Dr. Vadim Koshkin discussed bladder cancer advances, noting the NIAGARA trial showed improved survival with durvalumab + chemo in muscle-invasive disease. Enfortumab vedotin + pembrolizumab outperformed chemo in metastatic cases. HER2-targeted ADCs and future ADC-checkpoint combos show promise.